<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362012">
  <stage>Registered</stage>
  <submitdate>10/02/2012</submitdate>
  <approvaldate>24/02/2012</approvaldate>
  <actrnumber>ACTRN12612000237886</actrnumber>
  <trial_identification>
    <studytitle>PERTH IV MINOCYCLINE STROKE STUDY (PIMSS)</studytitle>
    <scientifictitle>PERTH IV MINOCYCLINE STROKE STUDY (PIMSS)

A phase II, multicentre prospective randomised open-label blinded endpoint evaluation (PROBE) pilot study of IV minocycline, 200mg daily for 2 days, for patients with ischaemic or haemorrhagic stroke, commencing within 24hours of symptom onset, compared with routine stroke care.</scientifictitle>
    <utrn>U1111-1128-0587</utrn>
    <trialacronym>PIMSS</trialacronym>
    <secondaryid>N/A</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ischaemic stroke</healthcondition>
    <healthcondition>Haemorrhagic stroke</healthcondition>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Ischaemic</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Ischaemic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Following randomisation, patients will be treated with either:
Intravenous Minocycline 100mg at Baseline and then 12 hourly for a total of 5 dose; or  routine stroke unit care.</interventions>
    <comparator>Routine Stroke unit Care (Best Practice)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Good neurological outcome (modified Rankin score=0-2) at 3 months</outcome>
      <timepoint>At 3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Categorical shift in modified Rankin score at 3 months</outcome>
      <timepoint>At 3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Age 18 years or older
2.Onset of stroke &lt; 24 hours.
3.Measurable neurological deficit on NHISS
4.Able to provide informed consent or
Next of Kin waver of consent for patients unable to provide voluntary consent due to stroke disability.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.Evidence of other significant CNS disease that interferes with assessment (eg tumor, multiple sclerosis)
2.Known allergy to tetracyclines/intolerance of minocycline.
3.Known systemic lupus erythrematosis.
4.Idiopathic intracranial hypertension.
5.Concurrent treatment with Vitamin A or retinoids.
6.Participation in another clinical drug trial.
7.Known significant  renal failure;  CLcr &lt; 30 mL/min by the Crockoft-Gault equation.
8.Known  significantly abnormal liver function tests (ALT &gt; x3 ULN) 
9.Thrombocytopaenia &lt; 100
10.Concurrent infection (at enrolment) requiring antibiotic treatment.	
11.Pregnancy.
12.Severe stroke or other co-morbidities likely to result in the patient dying within a week.
NB  thrombolytic therapy is NOT an exclusion criterion.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients will be drawn from those referred to the Stroke Units at the involved centers. Screening evaluation for suitability includes baseline history, physical examination, NIHSS, CT or MRI brain, blood tests and assessement of inclusion/exclusion criteria. After obtaining informed consent the admitting neurology doctor will use a randomisation table generated by pharmacy.</concealment>
    <sequence>Patients will be drawn from those referred to the Stroke Units at the involved centers. Screening evaluation for suitability includes baseline history, physical examination, NIHSS, CT or MRI brain, blood tests and assessement of inclusion/exclusion criteria. After obtaining informed consent the admitting neurology doctor will use a randomisation table generated by pharmacy. The research assistant will be notified of treatment allocation. A blinded assessor will perform NIHSS and record vital signs on day 1,2 and 7.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>10/02/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sir Charles Gairdner Hospital</primarysponsorname>
    <primarysponsoraddress>Sir Charles Gairdner Hospital
Hospital Avenue NEDLANDS 
Perth, WA 6009</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical research council (NHMRC)</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601
 
Postal
 National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Clin A/Prof David Blacker</fundingname>
      <fundingaddress>Department of Neurology
Sir Charles Gairdner Hospital
Perth, WA, 6009.</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal Perth Hospital</sponsorname>
      <sponsoraddress>Royal Perth Hospital
Wellington Street
Perth, WA,6000</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Swan Districts Hospital</sponsorname>
      <sponsoraddress>Swan Districts Hospital
Eveline Rd
Middle Swan, WA, 6056</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr David Blacker</othercollaboratorname>
      <othercollaboratoraddress>Dept of Neurology
Sir Charles Gairdner Hospital 
Nedlands  WA 6009</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr David Prentice</othercollaboratorname>
      <othercollaboratoraddress>Department of Internal medicine
Royal Perth Hospital
Wellington Street
Perth 6000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Graeme Hankey</othercollaboratorname>
      <othercollaboratoraddress>Stroke Unit
Royal Perth Hospital
Wellington Street
PERTH 6000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Edith Kohler</othercollaboratorname>
      <othercollaboratoraddress>Royal Perth Hospital
Wellington Street
PERTH 6000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Timothy Bates</othercollaboratorname>
      <othercollaboratoraddress>Stroke Unit
Swan Districts Hospital
Eveline Rd
Middle Swan, WA, 6056</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Anne Claxton</othercollaboratorname>
      <othercollaboratoraddress>Stroke Unit Royal Perth Hospital Wellington Street PERTH 6000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To test the hypothesis that acute stroke patients (both ischaemic and haemorrhagic) treated with IV minocycline within 24 hours of symptom onset have improved clinical outcomes compared with standard stroke care.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>HREC Royal Perth Hospital</ethicname>
      <ethicaddress>HREC Royal perth Hospital
level 5, Colonial House
Royal Perth Hospital
Wellington Street
perth WA 6000</ethicaddress>
      <ethicapprovaldate>18/12/2009</ethicapprovaldate>
      <hrec>2009/121</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>HREC Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress>The Human Research Ethics Commitee
Level 2, A-Block
Sir Charles Gairdner Hospital
Hospital Avenure Nedlands WA 6009</ethicaddress>
      <ethicapprovaldate>16/09/2010</ethicapprovaldate>
      <hrec>2010/004</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>HREC Swan Districts Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Edith Kohler</name>
      <address>Royal Perth Hospital
Wellington street
Perth, WA, 6000</address>
      <phone>+61 8 9224 2244</phone>
      <fax />
      <email>Edith_Kohler@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anne Claxton</name>
      <address>Stroke Unit Research
Level 8, A Block
Royal Perth Hospital
Wellington Street
Perth. WA. 6000</address>
      <phone>+61 8 9224 3461</phone>
      <fax />
      <email>anne.claxton@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Clin A/Prof David Blacker</name>
      <address>Department of Neurology
Sir Charles Gairdner Hospital
Perth, WA</address>
      <phone />
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>